Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Recruitment Status
WITHDRAWN
(See Contacts and Locations)Verified December 2025 by Methodist Health System
Sponsor
Methodist Health System
Information Provided by (Responsible Party)
Methodist Health System
Clinicaltrials.gov Identifier
NCT06222437
Other Study ID Numbers:
046.OBG.2023.D
First Submitted
January 15, 2024
First Posted
January 23, 2024
Last Update Posted
March 22, 2026
Last Verified
December 2025

ClinicalTrials.gov processed this data on March 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

The study mainly focused for the following objectives:

To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism.

To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.

Condition or DiseaseIntervention/Treatment
Polycystic Ovary Syndrome
Drug: Semaglutide

Study Design

0
Study TypeInterventional
Design AllocationN/A
Interventional ModelSingle Group Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleSemaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Study Start DateJanuary 31, 2026
Actual Primary Completion DateJanuary 31, 2026
Actual Study Completion Date9mos 2d from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Protocol group
PCOS women in the age 18 to 45 years
Drug: Semaglutide
effectiveness of semaglutide in PCOS

Outcome Measures

Primary Outcome Measures
  1. Number of appropriate weekly dose
    To access the compliances of the therapy
  2. Number of days on therapy
    To access the persistence on Semaglutide
Secondary Outcome Measures
  1. measure the Weight in kilograms
    To access the weight changes during therapy
  2. Numbers of days with exercise changes
    To access the ability to do exercise during the therapy

Eligibility Criteria

Ages Eligible for Study(Adult)
Sexes Eligible for StudyFemale
Accepts Healthy VolunteersNo
Inclusion Criteria
Age 18-45
Body mass index(BMI) \> 30
Diagnosis of PCOS
Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone
Exclusion Criteria
Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
Letrozole, clomiphene citrate, FSH therapy
Androgen receptor blockers
5α reductase inhibitors
Insulin
Hysterectomy
Endometrial ablation

Contacts and Locations

Sponsors and CollaboratorsMethodist Health System